Recombinant Mouse Jak2 Protein, Myc/DDK-tagged

• Cat.No.: Jak2-3627M
• Product Overview: Purified recombinant protein of mouse full-length Janus kinase 2 (Jak2), with C-terminal MYC/DDK tag, expressed in HEK293T cells.

Specification

• Description: Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.
• Source: HEK293T
• Species: Mouse
• Tag: Myc&DDK
• Molecular Mass: 131 kDa
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade after receiving vials.
• Concentration: >50 μg/mL as determined by microplate BCA method
• Storage Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.

Gene Information

• Gene Name: Jak2 Janus kinase 2 [ Mus musculus (house mouse) ]
• Official Symbol: Jak2
• Synonyms: JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JAK-2; Fd17; C81284; AI504024
• Gene ID: 16452
• mRNA Refseq: NM_001048177
• Protein Refseq: NP_001041642
• UniProt ID: Q62120

Reviews

10/03/2020

Quick response from customer service.

05/12/2020

Product performed as expected.

08/07/2018

Satisfied with product quality.

Q&As

What role does JAK2 play in myeloproliferative neoplasms (MPNs)?

JAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.

How does JAK2 activation lead to downstream signal transduction?

Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.

What is the primary function of the JAK2 protein in cellular signaling?

JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.

How is JAK2 involved in hematopoiesis and blood cell development?

JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.

How does JAK2 interact with cytokine receptors, and what is its significance?

JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.

Are there therapeutic agents that target JAK2, and in what contexts are they used?

Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.

Are there known mutations in the JAK2 gene, and what are their implications?

Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).